Catalent Inc
Change company Symbol lookup
Select an option...
CTLT Catalent Inc
SCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027
GMBL Esports Entertainment Group Inc
CFRX ContraFect Corp
AAL American Airlines Group Inc
NVDA NVIDIA Corp
AMD Advanced Micro Devices Inc
QQQ Invesco QQQ Trust
AAPL Apple Inc
BBBY Bed Bath & Beyond Inc
Go

Health Care : Pharmaceuticals | Mid Cap Blend
Company profile

Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.

Closing Price
$52.27
Day's Change
2.11 (4.21%)
Bid
--
Ask
--
B/A Size
--
Day's High
52.32
Day's Low
50.71
Volume
(Above Average)
Volume:
2,810,252

10-day average volume:
2,496,045
2,810,252

CTLT's position in the Pharmaceuticals industry

Industry PeersCTLTSCTL

Summary

Company ProfileCatalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics...
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing...
Go to SCTL summary
52-Week Change

VS. INDUSTRY
-46.73%
-11.76%
Market Cap

VS. INDUSTRY
$9.0B
$114.1M
Beta

VS. INDUSTRY
1.2
0.7
Dividend Yield

VS. INDUSTRY
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
21.46x
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$4.8B
$88.2M
Profit Margin

VS. INDUSTRY
8.83%
-14.81%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
26.67%
--
Revenue Growth (TTM)

VS. INDUSTRY
15.51%
40.13%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.